Log in to search using one of your social media accounts:

 

How CD44s gives brain cancer a survival advantage
(Baylor College of Medicine) In the case of glioblastoma multiforme, the deadliest type of brain cancer, researchers have discovered that the molecule CD44s seems to give cancer cells a survival advantage. In the lab, eliminating this advantage by reducing the amount of CD44s resulted in cancer cells being more sensitive to the deadly effects of the drug erlotinib. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 18, 2017 Category: Cancer & Oncology Source Type: news

Cabozantinib Improves Outcomes Over Erlotinib in Advanced NSCLC
Cabozantinib alone or in combination with erlotinib improved survival outcomes among patients with advanced EGFR wild-type non –small-cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - November 23, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Lung Cancer News Source Type: news

Blood pressure drug may boost effectiveness of lung cancer treatment
A blood pressure drug may make a type of lung cancer treatment more effective, suggests a new study. Almost 2 million people are diagnosed with lung cancer every year worldwide and it is the top international cancer killer. The team studied a lung cancer drug called erlotinib which can be used to treat between 10 and 30 per cent of lung cancer patients. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 27, 2016 Category: Science Source Type: news

Trial Shows Interactions Between KRAS Mutations, Erlotinib Therapy in NSCLC
A trial showed that KRAS wild-type NSCLC patients fare better with regimens containing erlotinib, while KRAS-mutated patients had better outcomes without erlotinib. (Source: CancerNetwork)
Source: CancerNetwork - August 1, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Lung Cancer News Source Type: news

Phase III data published in The Lancet Oncology shows a significant overall survival benefit of Giotrif < sup > ® < /sup > (afatinib) compared to Tarceva < sup > ® < /sup > (erlotinib) in patients with previously treated advanced squamous cell carcinoma of the lung
Phase III data published in The Lancet Oncology shows a significant overall survival benefit of Giotrif ® (afatinib) compared to Tarceva ® (erlotinib) in patients with previously treated advanced squamous cell carcinoma of the lung (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

Head-to-head Phase III trial demonstrates superior progression-free survival for afatinib compared to erlotinib in patients with advanced squamous cell carcinoma of the lung
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

ECC 2015: GIOTRIF < sup > ® < /sup > (afatinib) demonstrates superior survival compared to Tarceva < sup > ® < /sup > (erlotinib) for patients with previously treated advanced squamous cell carcinoma of the lung, independent of EGFR mutation status
ECC 2015: GIOTRIF ® (afatinib) demonstrates superior survival compared to Tarceva ® (erlotinib) for patients with previously treated advanced squamous cell carcinoma of the lung, independent of EGFR mutation status (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

Afatinib vs Erlotinib head-to-head trial results
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

ASCO 2015: Superior OS for afatinib vs erlotinib
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

Tarceva (Erlotinib) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 13, 2016 Category: Drugs & Pharmacology Source Type: news

June 6, 2016: Pharmaceutical Companies To Pay $67 Million To Resolve False Claims Act Allegations Relating To Tarceva
(Source: Office of Criminal Investigations (OCI) Press Releases)
Source: Office of Criminal Investigations (OCI) Press Releases - June 8, 2016 Category: Medical Law Source Type: news

Roche/Genentech, OSI to pay $67M to Settle Drug Claims
The claims alleged that between 2006 and 2011, the companies misrepresented Tarceva (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - June 8, 2016 Category: Pharmaceuticals Source Type: news

Roche receives EU approval of Avastin in combination with Tarceva for patients with a specific type of advanced lung cancer
Roche announced today that the European Commission has approved the use of Avastin® (bevacizumab) in combination with Tarceva® (erlotinib) for the first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR)-activating mutations. (Source: Roche Media News)
Source: Roche Media News - June 8, 2016 Category: Pharmaceuticals Source Type: news

Roche receives EU approval of Avastin in combination with Tarceva for patients with a specific type of advanced lung cancer
Roche announced today that the European Commission has approved the use of Avastin® (bevacizumab) in combination with Tarceva® (erlotinib) for the first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR)-activating mutations. (Source: Roche Investor Update)
Source: Roche Investor Update - June 8, 2016 Category: Pharmaceuticals Source Type: news

IASLC pleased by FDA approval of blood test to detect mutations in lung cancer
(International Association for the Study of Lung Cancer) The International Association for the Study of Lung Cancer praises the US Food and Drug Administration's decision to approve the first blood test to detect an oncogenic driver mutation in non-small cell lung cancer. This marks a significant step forward in lung cancer treatment. The cobas EGFR Mutation Test v2 detects epidermal growth factor receptor gene mutations and the FDA approved a blood-based companion diagnostic for the EGFR tyrosine kinase inhibitor erlotinib (Tarceva). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 8, 2016 Category: Global & Universal Source Type: news

Morning Break: Olympic Zika Risk Overblown; Tarceva Marketers Fined; Gut Robot
(MedPage Today) -- Health news and commentary from around the Web, gathered by the MedPage Today staff (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - June 7, 2016 Category: Infectious Diseases Source Type: news

Genentech and OSI to pay $67m to resolve False Claims Act allegations for Tarceva
US-based pharmaceutical companies Genentech and OSI Pharmaceuticals will pay $67m in order to resolve False Claims Act allegations regarding misleading statements made about the effectiveness of Tarceva for treating non-small cell lung cancer. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - June 6, 2016 Category: Pharmaceuticals Source Type: news

FDA OKs First Liquid Biopsy for Lung Cancer Mutation FDA OKs First Liquid Biopsy for Lung Cancer Mutation
The blood-based genetic test is a companion diagnostic for erlotinib and for use in patients with non-small cell lung cancer. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 1, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA approves first blood test to detect gene mutation associated with non-small cell lung cancer
The U.S. Food and Drug Administration today approved the cobas EGFR Mutation Test v2, a blood-based companion diagnostic for the cancer drug Tarceva (erlotinib). This is the first FDA-approved, blood-based genetic test that can detect epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer patients. Such mutations are present in approximately 10-20 percent of non-small cell lung cancers (NSCLC). (Source: Food and Drug Administration)
Source: Food and Drug Administration - June 1, 2016 Category: American Health Source Type: news

FDA approves first blood test to detect gene mutation associated with non-small cell lung cancer
June 1, 2016 -- The U.S. Food and Drug Administration today approved the cobas EGFR Mutation Test v2, a blood-based companion diagnostic for the cancer drug Tarceva (erlotinib). This is the first FDA-approved, blood-based genetic test that can... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 1, 2016 Category: Pharmaceuticals Source Type: news

Additional Treatments Offer Little Benefit for Pancreatic Cancer: Study
TUESDAY, May 3, 2016 -- Additional treatments for locally advanced pancreatic cancer don't appear to boost survival, a new French study reports. Researchers looked at the effects of adding a second drug -- erlotinib (Tarceva) -- to the initial... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 3, 2016 Category: Journals (General) Source Type: news

Chemoradiotherapy vs. chemotherapy for locally advanced pancreatic cancer
(The JAMA Network Journals) In a study appearing in the May 3 issue of JAMA, Pascal Hammel, M.D., of Beaujon Hospital, Clichy, France and colleagues assessed whether chemoradiotherapy improves overall survival of patients with locally advanced pancreatic cancer controlled after four months of gemcitabine-based induction chemotherapy, and assessed the effect of erlotinib on survival. Gemcitabine and erlotinib are drugs used to treat cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 3, 2016 Category: Cancer & Oncology Source Type: news

CHMP recommends EU approval for Roche's Avastin in combination with Tarceva for patients with a specific type of advanced lung cancer
Roche announced today that the European Union’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the use of Avastin® (bevacizumab) in combination with Tarceva® (erlotinib) for the first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) activating mutations. (Source: Roche Media News)
Source: Roche Media News - April 29, 2016 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval for Roche's Avastin in combination with Tarceva for patients with a specific type of advanced lung cancer
Roche announced today that the European Union’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the use of Avastin® (bevacizumab) in combination with Tarceva® (erlotinib) for the first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) activating mutations. (Source: Roche Investor Update)
Source: Roche Investor Update - April 29, 2016 Category: Pharmaceuticals Source Type: news

FDA approves Gilotrif® (afatinib) as new oral treatment option for patients with squamous cell carcinoma of the lung
• Approval provides a new second-line treatment option for patients with the second largest sub-type   of non-small cell lung cancer (NSCLC), representing about 20-30% of NSCLC cases • Approval is based on results of the LUX-Lung 8 study, which showed significantly improved overall   survival and progression-free survival compared to Tarceva® (erlotinib) in patients with squamous cell  carcinoma of the lung • Gilotrif is already approved in more than 60 countries for the treatment of patients with distinct types  of EGFR mutation-positive NSCLC (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - April 14, 2016 Category: Research Source Type: news

Giotrif® (afatinib) approved in Europe as new oral treatment option for patients with squamous cell carcinoma of the lung
• Approval provides a new oral treatment option for patients with the second largest sub-type of non-small cell lung cancer (NSCLC), representing approximately 20-30% of NSCLC cases.1,2• Approval of Giotrif® is based on results of the LUX-Lung 8 study, which showed significantly improved overall survival and progression-free survival compared to Tarceva® (erlotinib) in patients with squamous cell carcinoma of the lung3• Afatinib is already approved in more than 60 countries for the treatment of patients with EGFR mutation-positive NSCLC* (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 6, 2016 Category: Research Source Type: news

Cranial Irradiation in EGFR-Mutant NSCLC Brain MetastasesCranial Irradiation in EGFR-Mutant NSCLC Brain Metastases
Is erlotinib plus radiotherapy superior to either therapy alone for brain metastases associated with NSCLC? Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 4, 2016 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Drug combination reduces polyps for patients with high risk for colorectal cancer
In a recent study, researchers randomly assigned 92 patients with familial adenomatous polyposis to the drugs sulindac twice daily and erlotinib daily (n = 46) or placebo (n = 46) for 6 months. The outcome of the study showed very positive results for those with a high risk of colorectal cancer (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 22, 2016 Category: Science Source Type: news

Sulindac plus erlotinib reduces duodenal polyp burden
Combination therapy with sulindac and erlotinib reduced the burden of duodenal polyps in a preliminary study involving 92 patients with familial adenomatous polyposis (FAP), which was reported online... (Source: Family Practice News)
Source: Family Practice News - March 22, 2016 Category: Primary Care Source Type: news

Drug combination reduces polyps for patients with high risk for colorectal cancer
(The JAMA Network Journals) In a study appearing in the March 22/29 issue of JAMA, Deborah W. Neklason, Ph.D., N. Jewel Samadder, M.D., M.S., of the Huntsman Cancer Institute, University of Utah, Salt Lake City, and colleagues randomly assigned 92 patients with familial adenomatous polyposis to the drugs sulindac twice daily and erlotinib daily (n = 46) or placebo (n = 46) for 6 months. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 22, 2016 Category: Cancer & Oncology Source Type: news

Erlotinib cost-effective option in EGFR-mutated NSCLC
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2016 Category: Drugs & Pharmacology Source Type: news

Could a Lung Cancer Drug Work Better With Coke?
Study finds cola boosts effectiveness of Tarceva for patients who are also taking a heartburn medicine (Source: Cancercompass News: Other Cancer)
Source: Cancercompass News: Other Cancer - February 14, 2016 Category: Cancer & Oncology Source Type: news

Could a Lung Cancer Drug Work Better With Coke?
Study finds cola boosts effectiveness of Tarceva for patients who are also taking a heartburn medicine (Source: WebMD Health)
Source: WebMD Health - February 12, 2016 Category: Consumer Health News Source Type: news

Could a Lung Cancer Drug Work Better With Coke?
Study finds cola boosts effectiveness of Tarceva for patients who are also taking a heartburn medicine (Source: U.S. News - Health)
Source: U.S. News - Health - February 12, 2016 Category: Consumer Health News Source Type: news

Could a Lung Cancer Drug Work Better With Coke?
Study finds cola boosts effectiveness of Tarceva for patients who are also taking a heartburn medicine (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 12, 2016 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Gastroenterology, Nursing, Oncology, News, Source Type: news

Medtech approvals: FDA releases November 2015 PMAs
The FDA today released its list of the pre-market approvals it granted for medical devices in November 2015: Summary of PMA Originals & Supplements Approved Originals: 3 Supplements: 69 Summary of PMA Originals Under Review Total Under Review: 57 Total Active: 30 Total On Hold: 27 Summary of PMA Supplements Under Review Total Under Review: 583 Total Active: 433 Total On Hold: 150 Summary of All PMA Submissions Originals: 4 Supplements: 75 Summary of PMA Supplement PMA Approval/Denial Decision Times Number of Approvals: 69 Number of Denials: 0 Average Days Fr Receipt to Decision (Total Time): 193.4 FDA Tim...
Source: Mass Device - January 22, 2016 Category: Medical Equipment Authors: MassDevice Tags: Food & Drug Administration (FDA) Regulatory/Compliance Source Type: news

Delhi HC upholds Roche's patent claims on Tarceva against Cipla
In a statement to ET, Roche said it welcomed the decision of the court, which has upheld the patent covering erlotinib hydrochloride. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 27, 2015 Category: Pharmaceuticals Source Type: news

Erlotinib Fails at Chemoprevention of Oral CancerErlotinib Fails at Chemoprevention of Oral Cancer
In the first precision-based chemoprevention study, erlotinib failed to significantly prevent the development of oral cancer in patients with oral premalignant lesions. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 5, 2015 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

First Precision Medicine Chemoprevention Trial DisappointsFirst Precision Medicine Chemoprevention Trial Disappoints
In the first precision-based chemoprevention study, erlotinib failed to significantly prevent the development of oral cancer in patients with oral premalignant lesions. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 5, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Metabolic Tumor Heterogeneity Hints at NSCLC PrognosisMetabolic Tumor Heterogeneity Hints at NSCLC Prognosis
Can glucose metabolic heterogeneity signal prognosis in non-small cell lung cancer (NSCLC) patients treated with erlotinib? Medscape Radiology (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - October 15, 2015 Category: Radiology Tags: Radiology Viewpoint Source Type: news

Erlotinib cost effective for NSCLC in the US
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - October 1, 2015 Category: Drugs & Pharmacology Source Type: news

erlotinib, Tarceva
Title: erlotinib, TarcevaCategory: MedicationsCreated: 11/28/2004 12:00:00 AMLast Editorial Review: 7/21/2015 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - July 21, 2015 Category: Cancer & Oncology Source Type: news

Erlotinib therapy based on EGFR mutation status cost effective
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 1, 2015 Category: Drugs & Pharmacology Source Type: news

[Research Article] Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer
Triple antibody targeting of multiple receptors subverts the resistance induced by single-agent therapies in lung cancer. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - June 1, 2015 Category: Science Authors: Maicol Mancini, Nadège Gaborit, Moshit Lindzen, Tomer Meir Salame, Massimiliano Dall'Ora, Michal Sevilla-Sharon, Ali Abdul-Hai, Julian Downward, Yosef Yarden Source Type: news

Kidney cancer patients respond well to a combination of 2 existing anti-cancer drugs
(ECCO-the European CanCer Organisation) Researchers have found that patients with an advanced form of kidney cancer, for which there is no standard treatment and a very poor prognosis, respond well to a combination of two existing anti-cancer drugs. The 26th EORTC-NCI-AACR Symposium will hear that the combination of bevacizumab and erlotinib produced excellent response rates in patients with advanced papillary renal cell carcinoma (pRCC) and in patients with a highly aggressive form of pRCC called hereditary leiomyomatosis and renal cell cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 18, 2014 Category: Cancer & Oncology Source Type: news

Why targeted drug doesn't benefit patients with early-stage lung cancer
This study might explain why. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - October 27, 2014 Category: Science Source Type: news

Study may explain why targeted drug doesn't benefit patients with early-stage lung cancer
This study might explain why. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 27, 2014 Category: Cancer & Oncology Source Type: news

PET Imaging for Tyrosine Kinase Inhibitor (TKI) Biodistribution in Mice
Receptor tyrosine kinases play a critical role in cell growth, survival, and proliferation, and are considered potential molecular targets for the treatment of cancer. Although several tyrosine kinase inhibitors (TKIs), such as erlotinib and gefitinib, have demonstrated clinical efficacy via the inhibition of the epidermal growth factor receptor (EGFR), most TKIs are only effective in a small proportion of patients. Positron emission tomography (PET) imaging is a methodology of molecular imaging based on nuclear imaging. PET imaging in combination with radiolabeled TKIs improves accuracy of quantitative imaging strategies ...
Source: Springer protocols feed by Cancer Research - October 15, 2014 Category: Cancer & Oncology Source Type: news